trending Market Intelligence /marketintelligence/en/news-insights/trending/uic-uHsgfdxUMOcvF-hgrw2 content esgSubNav
In This List

Kaleido BioSciences seeking up to $100M in Nasdaq IPO

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Kaleido BioSciences seeking up to $100M in Nasdaq IPO

Kaleido BioSciences Inc. is planning to raise up to $100 million in an IPO on Nasdaq.

The Lexington, Mass.-based biotechnology company, whose pipeline includes medicines for infections caused by drug-resistant bacteria, heart and kidney diseases, and diarrhea, plans to list its shares on the Nasdaq Global Select Market under the symbol KLDO.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Canaccord Genuity LLC are the underwriters of the IPO and will have an option to buy additional shares in the offering.